The Study Included 197 Women, 101 for TOLAC and 96 for ERCD

Total Page：16

File Type：pdf, Size：1020Kb

The Study Included 197 Women, 101 for TOLAC and 96 for ERCD

Repeat Cesarean or Trial of Labor? Factors Influencing a Patient’s Delivery Decision after Previous Cesarean Section Meir Pomeranz MD1,Nisim Arbib MD1, Limor Haddif RN, MA1, Hana Reissner MS2, Yitzhak Romem MD3, Tal Biron MD1 1Department of Obstetrics and Gynecology, Meir Hospital, Kfar Saba, Israel affiliated with Tel Aviv University Sackler Faculty of Medicine 2Sackler School of Medicine New York/American Program at Tel Aviv University, Tel Aviv, Israel 3Department of Obstetrics and Gynecology, Laniado Hospital, Netanya, Israel ObjectiveBackground Results To investigate factors influencing The study included 197 women, 101 for TOLAC and 96 for ERCD. Women who chose TOLAC were more women's choice of trial of labor religious, wanted more children and had higher Internal and Chance health locus of control. Women who after cesarean (TOLAC) or elective chose ERCD were more likely to be secular and had a higher health locus of control influenced by Powerful repeat cesarean delivery (ERCD) Others, most notably physicians. Women who reported being influenced by physicians were more likely to based on the Multidimensional choose ERCD. Women not influenced by others were likelier to choose TOLAC. Health Locus of Control (MHLC), 4.50 religious observance, and family 4.20 4.20 Conclusion 4.00 3.83 planning. 3.65 A woman’s choice of TOLAC or ERCD is 3.50 3.33 3.33 3.21 influenced by her sense of control over her 3.00 Methods 2.74 health, degree of religious observance, and Cross-sectional study of women at 2.50 number of children desired. Health care 2.00 providers can use this information to better Meir Medical Center and Laniado 1.50 understand, counsel, and educate their Hospital in Israel who were patients on the appropriate delivery decision. 1.00 candidates for TOLAC or ERCD. If a woman feels in control over her health, .50 educated about delivery options, and is less Women completed a demographic .00 influenced by provider preference, more Internal External (Force) External (Chance) Spirituality questionnaire and a questionnaire women might choose TOLAC; thus reducing using Form C of the MHLC scale VBAC ERCD the rate of unnecessary ERCD..

Copy Link

Recommended publications

Rare Cause of Abdominal Pain in Cystic Fibrosis
BMJ Case Reports: first published as 10.1136/bcr-2013-201259 on 12 November 2013. Downloaded from Images in… Transient intussusception: rare cause of abdominal pain in cystic fibrosis Suheil Artul,1,2 Faozi Artoul,3 George Habib,4 Nabil Abboud5 1Department of Radiology, DESCRIPTION Nazareth Hospital, Nazareth, A 26-year-old man with history of cystic fibrosis, Israel 2Faculty Medicine in the presented to the emergency department with a Galilee, Bar-Ilan University, 2-day history of abdominal pain, nausea and vomit- Safed Israel, Maghar, Israel ing. The patient did not have a history of abdom- 3 Department of Nuclear inal surgery. Medicine, Meir Hospital, On presentation the patient was afebrile and Maghar, Israel 4Department of Medicine, normotensive. Abdominal examination revealed Nazareth Hospital, Nazareth, tenderness in the mid-abdomen and no rebound. Israel Laboratory tests showed slight leucocytosis and 5 Department of Surgery, normal level of amylase. Abdominal plain radio- Nazareth Hospital, Nazareth, Israel graph showed gaseous distention of multiple small bowel loops. Contrast CT of the abdomen showed Correspondence to total fatty replacement of the pancreas (figure 1, Dr Suheil Artul, white arrows), dilated small bowel loops up to [email protected] 4.5 cm in diameter (figure 2, red arrows) and a ‘solid mass’ of 6 cm in long axis ‘cobra head sign’ Figure 2 Contrast-enhanced CT of the abdomen showing (figure 2, black arrows) indicating ileo-ileal intus- dilated small bowel loops up to 4.5 cm in diameter (red susceptions, without any sign of bowel wall suffer- arrows), a ‘solid mass’ of6cminlongaxis‘cobra head sign’ ing such as air or oedema of the involved loop.
[Show full text]
Spotted Fever Group Rickettsioses in Israel, 2010–2019
Spotted Fever Group Rickettsioses in Israel, 2010–2019 Regev Cohen, Talya Finn, Frida Babushkin, Yael Paran, Ronen Ben Ami, Alaa Atamna, Sharon Reisfeld, Gabriel Weber, Neta Petersiel, Hiba Zayyad, Eyal Leshem, Miriam Weinberger, Yasmin Maor, Nicola Makhoul, Lior Nesher, Galia Zaide, Dar Klein, Adi Beth-Din, Yafi t Atiya-Nasagi ≈ In a multicenter, nationwide, retrospective study of pa- SFGRs are associated with 20 species of Rickettsia, tients hospitalized with spotted fever group rickettsiosis of which 16 are considered human pathogens (1,2). in Israel during 2010–2019, we identifi ed 42 cases, of Recent introduction of molecular methods provided which 36 were autochthonous. The most prevalent spe- more information about SFGR agents causing human cies was the Rickettsia conorii Israeli tick typhus strain (n disease and enabled their identifi cation, for which = 33, 79%); infection with this species necessitated inten- the clinical signifi cance of some remains lacking (3). sive care for 52% of patients and was associated with a R. conorii complex, the etiologic agent of Mediterra- 30% fatality rate. A history of tick bite was rare, found for nean spotted fever, includes 4 strains: R. conorii Mal- only 5% of patients; eschar was found in 12%; and leuko- ish (cause of Mediterranean spotted fever), R. conorii cytosis was more common than leukopenia. Most (72%) Astrakhan (cause of Astrakhan fever), R. conorii In- patients resided along the Mediterranean shoreline. For 3 dian tick typhus (cause of Indian tick typhus), and R. patients, a new Rickettsia variant was identifi ed and had been acquired in eastern, mountainous parts of Israel.
[Show full text]
Scientific Program
The 63th Annual Conference of the Israel Heart Society in association with the Israel Society of Cardiothoracic Surgery April 12-13 • 2016 • Tel Aviv, Israel SCIENTIFIC PROGRAM Paragon Israel (Dan Knassim) Paragon Tel/Fax:03-5767730/7 Israel (Dan Knassim) a Paragon Group Company [email protected] TUESDAY, APRIL 12, 2016 08:30-10:00 Interventional Cardiology I Hall A Chairs: Ariel Finkelstein, Ran Kornowski, Israel 08:30 Effect of Diameter of Drug-Eluting Stents Versus Bare-Metal Stents on Late Outcomes: a propensity score-matched analysis Amos Levi1,2, Tamir Bental1,2, Hana Veknin Assa1,2, Gabriel Greenberg1,2, Eli Lev1,2, Ran Kornowski1,2, Abid Assali1,2 1Cardiology, Rabin Medical Center, Israel 2Sackler Faculty of Medicine, Tel Aviv University, Israel 08:41 Percutaneous Valve-in-Valve Implantation for the Treatment of Aortic, Mitral and Tricuspid Structural Bioprosthetic Valve Degeneration Uri Landes1, Abid Assali1, Ram Sharoni1,2, Hanna Vaknin-Assa1, Katia Orvin1, Amos Levi1, Yaron Shapira1, Shmuel Schwartzenberg1, Ashraf Hamdan1, Tamir Bental1, Alexander Sagie1, Ran Kornowski1 1Department of Cardiology, Rabin Medical Center, Tel Aviv, Israel 2Department of Cardiac Surgery, Rabin Medical Center, Tel Aviv, Israel 08:52 Temporal Trends in Transcatheter Aortic Valve Implantation in Israel 2008-2014: Patient Characteristics, Procedural Issues and Clinical Outcome Uri Landes1, Alon Barsheshet1, Abid Assali1, Hanna Vaknin-Assa1, Israel Barbash3, Victor Guetta3, Amit Segev3, Ariel Finkelstein2, Amir Halkin2, Jeremy Ben-Shoshan2,
[Show full text]
Antibiotic Treatment for Invasive Listeriosis and Patient
Antibiotic treatment for invasive listeriosis and patient outcome: a retrospective cohort study Yaakov Dickstein1, Yonatan Oster2, Orit Shimon3, Lior Nesher4, Dafna Yahav3,5, Yonit Wiener-Well6, Regev Cohen7,8, Ronen Ben-Ami3,9, Miriam Weinberger3,10, Galia Rahav3,11, Yasmin Maor3,12, Michal Chowers3,13, Ran Nir-Paz2, Mical Paul1,8 1 Institute of Infectious Diseases, Rambam Health Care Campus, Haifa, Israel 2 Department of Clinical Microbiology and Infectious Diseases, Hadassah-Hebrew University Medical Center, Jerusalem, Israel 3 Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel 4 Infectious Disease Institute, Soroka Medical Center, Ben-Gurion University of the Negev, Beer Sheba, Israel 5 Infectious Diseases Unit, Rabin Medical Center, Beilinson hospital, Petah-Tikva, Israel 6 Infectious Disease Unit, Shaare Zedek Medical Center, Jerusalem, Israel 7 Infectious Diseases Unit, Sanz Medical Center–Laniado Hospital , Netanya, Israel 8 The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel 9 Infectious Diseases Unit, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel 10 Infectious Diseases Unit, Assaf Harofeh Medical Center, Zerifin, Israel 11 Infectious Disease Unit, Sheba Medical Center, Ramat Gan, Israel 12 Infectious Disease Unit, Wolfson Medical Center, Holon, Israel 13 Infectious Diseases Unit, Meir Medical Center, Kfar Saba, Israel Cumulative survival by treatment group Background: Current treatment started within 48 hours of culture recommendations for treatment of results and continued for a minimum duration invasive listeriosis suggest ampicillin- of 7 days. Patients who died within 48 hours of based therapy with the addition of an the index culture were excluded. The primary aminoglycoside. However, several outcome was 30-day all-cause mortality.
[Show full text]
Cyclosporin for Severe Ulcerative Colitis
Original Articles Cyclosporin for Severe Ulcerative Colitis Timna Naftali MD1, Ben Novis MD1, Itamar Pomeranz MD1, George Leichtman MD1, Yaakov Maor MD1, Rivka Shapiro MD2, Menachem Moskowitz MD3, Beni Avidan MD4, Yona Avni MD5, Yoram Buja- nover MD6 and Zvi Fireman MD7 1Department of Gastroenterology, Meir Hospital, Kfar Saba, 2Department of Pediatric Gastroenterology, Schneider Childrens Medical Center, Petah Tiqva, 3Department of Gastroenterology, Tel Aviv Sourasky Medical Center, Tel Aviv, 4Department of Gastroenterology, Sheba Medical Center, Tel-Hashomer, Departments of 5Gastroenterology and 6Pediatrics, Wolfson Hospital, Holon, and 7Department of Gastroenterology, Hillel Yaffe Hospital, Hadera, Israel Key words: cyclosporin, ulcerative colitis, colectomy, corticosteroids For Editorial see page 607 oids both rectally and intravenously [1]. About 30% of patients with severe ulcerative colitis do not respond to Abstract this treatment and require urgent total colectomy [2]. It was recently shown that cyclosporin is effective in this Background: About one-third of patients with severe group of patients. However, experience is limited and the ulcerative colitis do not respond to conventional therapy numbers of patients reported are relatively small. The aim and require urgent colectomy. It was recently shown that of this study was to review the experience with cyc- cyclosporin is effective in some of these patients. losporin for the treatment of severe ulcerative colitis in Objectives: To review the current experience of six six hospitals in Israel. hospitals in central Israel that used cyclosporin in patients with severe ulcerative colitis. Patients and Methods Methods: The files of all 32 patients treated with cyc- The files of all 32 patients treated with cyclosporin for losporin for corticosteroid-resistant ulcerative colitis were ulcerative colitis in six hospitals in central Israel were reviewed.
[Show full text]
APF Newsletter, Winter 2006 – 2007
Winter 2006-2007 APF A Newsletter of the From The President AmericanEmergency Physicians andFellowship Disaster Preparednessfor Medicine in Israel Course News in Israel From The President Israel in Crisis Mission August 2006 would like to share with our members and donors the important by Dr. Dan Moskowitz I APF activities of the past 6 months. his past August, I had the privilege of being invited to par- 1. APF ISRAEL CRISIS FUND REPORT After placing on our T ticipate in an Emergency APF Mission to Israel with APF website and sending a special crisis appeal from Dr. Danny Laor, Board members Drs. Mike Frogel, Paul Liebman and Charles the Deputy Minister for Emergency Preparedness, on the critical Kurtzer. Dr. Boaz Tadmor organized an incredible, whirlwind needs of the Northern hospitals, it was very gratifying indeed that over $100,000 tour for us, only two days after the cessation of hostilities in was received for our Crisis Fund. All of this will be distributed to hospitals such as Israel. We were provided with a unique glimpse of the Israeli Sieff Hospital in Safed, Poriya in Tiberias, Western Galilee Medical Center in Nahariya, and Rambam Medical Center in Haifa, with the hospital CEO’s given the healthcare system under stress, including face-to-face meet- discretion as to how best to utilize these funds to help their hospital in light of the ings with top healthcare officials, as well as visits to the trau- recent crisis. matized hospitals in northern Israel. Perhaps most importantly, we visited 2. MISSION TO ISRAEL Three APF Board members, Drs.
[Show full text]
BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
BMJ Open: first published as 10.1136/bmjopen-2020-040210 on 8 February 2021. Downloaded from BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] http://bmjopen.bmj.com/ on September 26, 2021 by guest. Protected copyright. BMJ Open BMJ Open: first published as 10.1136/bmjopen-2020-040210 on 8 February 2021. Downloaded from PipEracillin Tazobactam versus mERoPENem for treatment of bloodstream infections caused by cephalosporin-resistant Enterobacteriaceae - a non-inferiority randomized controlled trial (PeterPen) ForJournal: peerBMJ Open review only Manuscript ID bmjopen-2020-040210 Article Type: Protocol Date Submitted
[Show full text]
YEHUDA SHOENFELD, MD, FRCP(Hon.)
YEHUDA SHOENFELD, M.D., FRCP(Hon.) CURRICULUM VITAE 2013 Chaim Sheba Medical Center The Zabludowicz Center for Autoimmune Diseases Tel Hashomer 52621, Israel Incumbent of the Laura Schwarz-Kipp Chair for Research of Autoimmune Diseases, Sackler Faculty of Medicine, Tel-Aviv University, Israel. Tel: 03-5302661 Fax: 03-5352855 E-mail: [email protected] - 2 - CURRICULUM VITAE YEHUDA SHOENFELD, M.D. Date and place of birth: February 14, 1948, Slovakia. Marital Status: Married + 3 (Nettea, Amir, Guy) EDUCATION 1965 - 1972 Hadassa Medical School, Hebrew University, Jerusalem 1972 - M.D. Thesis: "Osteogenesis Imperfecta" (Advisor: Prof. A. Fried) cum laude 1976 - 1978 Diploma cum laude upon completion of post graduate studies in internal medicine, Postgraduate Medical School, Tel Aviv University 1976 - Senior resident, Department of Internal Medicine "D" and Out-Patient Clinic of Hematology and Immunology, Beilinson Medical Center, Petach Tikva, Israel 1978 (3m) - Clinical Fellowship, Hematology/Oncology, Department of Hematology, City of Hope, Duarte, California (Director: Prof. E. Beutler) 1979 (3m) - Clinical Fellowship Hematology/Oncology, Tufts New England Medical Center, Boston, Mass. (Director: Prof. Robert S. Schwartz) 1980 (3m) - Clinical Fellowship Hematology/Oncology, Cornell Medical Center, New York Hospital (Director: Prof. R. Nachman) 1980 - Master in Internal Medicine, Postgraduate Medical School, Tel-Aviv University 1983 - 1984 Senior Physician, department of Internal Medicine "D", Beilinson Medical Center, Petach Tikva, Israel 1985 - Head, Department of Medicine "D" and Outpatient Clinic for Clinical Immunology and Allergy, Soroka Medical Center, Beer-Sheva, Israel 1985 - Head of the Hybridoma Unit and Research Laboratory for Autoimmune Diseases, Soroka Medical Center, and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel 1989 - Head of Department of Medicine "B" Sheba Medical Center, Tel-Hashomer and Sackler Faculty of Medicine, Tel-Aviv University, Israel.
[Show full text]
Neuro-Ophthalmology in Israel
Worldwide Neuro-Opthalmology Section Editor: Kathleen B. Digre, MD Neuro-Ophthalmology in Israel Ruth Huna-Baron, MD, Eitan Zvi Rath, MD FIG. 1. Pioneers of neuro-ophthalmology in Israel. euro-ophthalmology was introduced in Israel during challenge of the rapid development of new and expensive N the late 1970s by Riri Manor, Yochanan Goldhammer, diagnostic and therapeutic modalities, a committee of the and Isaac Gutman (Fig. 1). They trained with from William Ministry of Health each year announces new technologies Hoyt, Lawton Smith, and Myles Behrens, respectively. These and therapies to be included in basic health coverage. There pioneers trained many local ophthalmologists, neurologists, are 18 magnetic resonance imaging devices in Israel and 5 and neuro-ophthalmologists in Israel, and their efforts resulted interventional neurovascular units, and most medical in 21 neuro-ophthalmologists currently serving a population centers in the country have a neuro-ophthalmology service of 8 million. Many Israeli neuro-ophthalmologists did fellow- (Table 1). Much like in the United States, referrals come ships in the United States with a variety of other mentors, from neurologists, ophthalmologists, neurosurgeons inter- including Ronald Burde, Joel Glaser and Norman Schatz, ventional neuroradiologists, and endocrinologists. Mark Kupersmith, Byron Lam, Neil Miller, Barry Scarf, In 1997, the Israeli Neuro-Ophthalmology Society was and Jonathan Trobe. founded by Ririo Manor as a subspecialty section of the In Israel, each citizen is entitled to health care services Israeli Ophthalmology Society. Two annual meetings are under the National Health Insurance Law. To meet the organized by the society, of which one hosts a leading TABLE 1.
[Show full text]
P2463 Antibiotic Treatment for Invasive Listeriosis and Patient
P2463 Antibiotic treatment for invasive listeriosis and patient outcome: a retrospective cohort study Yaakov Dickstein*1, Yonatan Oster2, Orit Shimon3, Lior Nesher4, Dafna Yahav5,3, Yonit Wiener-Well6, Regev Cohen7,8, Ronen Ben-Ami9,3, Miriam Weinberger10,3, Galia Rahav11,3, Yasmin Maor12,3, Michal Chowers13,3, Ran Nir-Paz2, Mical Paul8,14 1 Rambam Healthcare Campus, Haifa, Israel, 2 Hadassah University Hospital - Ein Kerem, Jerusalem, Israel, 3 Tel Aviv University, Sackler Faculty of Medicine, Ramat Aviv, Israel, 4 Soroka Medical Center, Beersheba, Israel, 5 Rabin Medical Center, Petah Tikva, Israel, 6 Shaare Zedek, Jerusalem, Israel, 7 Laniado Hospital, Netanya, Israel, 8 Technion, The Ruth and Bruce Rappaport Faculty of Medicine, Haifa, Israel, 9 Tel Aviv Sourasky Medical Center , Tel Aviv, Israel, 10 Assaf Harofeh Medical Center, Be’er Ya’akov, Israel, 11 Sheba Medical Center, Ramat Gan, Israel, 12 Wolfson Medical Center, Holon, Israel, 13 Meir Medical Center, Kefar Sava, Israel, 14 Infectious Diseases Unit, Rambam Health Care Campus, Haifa, Israel Background: Current recommendations for treatment of invasive listeriosis suggest ampicillin-based therapy with the addition of an aminoglycoside. However, several reports have suggested higher morbidity and mortality with this regimen as compared with beta-lactam monotherapy. We aimed to evaluate the association between penicillin-aminoglycoside combination therapy and mortality in patients with invasive listeriosis while adjusting for timing of treatment onset. Materials/methods: This is a multicenter retrospective observational study of adult patients with invasive listeriosis (primary bacteremia, central nervous system [CNS] disease and pregnancy-associated listeriosis) in 11 hospitals in Israel between the years 2008-2014. We evaluated the effect of penicillin-based monotherapy compared with early combination therapy with gentamicin, defined as treatment started within 48 hours of culture results and continued for a minimum duration of 7 days.
[Show full text]
General Hospital Beds in Israel
Overview Date: 13 Kislev 5780, 11 December 2019 Written by: Aharon Blank, Flora Koch Davidovich | Approved by: Shelly Levy, Team Leader General hospital beds in Israel There are 45 general hospitals in Israel, a quarter of which are government-owned (nine government hospitals and two government–municipal hospitals).1 A general hospital is comprised of the following wards: internal medicine, intensive care, pediatrics, surgery, maternity wards, and intermediate care wards. Israel has a shortage of beds in general hospitals; for many years, various parties—including the State Comptroller—have noted the gap between the demands made of the system of general hospitals and the resources allocated to it, and they have called for long-term planning of the system of general hospitals in Israel.2 According to data from the Ministry of Health, in January 2019 there were 16,021 acute care beds in Israel—15,871 in general hospitals and 151 in geriatric hospitals. The rate of acute care beds in Israel has been declining since the late 1970s; as of 2019, it stands at 1.78 beds per 1,000 people, as compared to 1.88 in 2011 and 2.09 in 2005.3 Ministry of Health data from January 2019 on the geographic distribution of acute care beds indicates that nearly half are located in the central district (23.8%) and Tel Aviv (21.4%), while the remaining beds are in the Haifa district (15.2%), Jerusalem (14.5%), the northern district (12.7%) and the southern district (12.3%).4 A comparison of the rate of acute care beds in hospitals per 1,000 people in Israel to the rate in 34 OECD member states, based on data from 2017,5 indicates a decline in the rate of acute care beds in hospitals in OECD countries due to technological developments and the expansion of community healthcare services, among other things.
[Show full text]
Severe Recurrent Pancreatitis in a Child with ADHD After Starting Treatment with Methylphenidate (Ritalin)
Hindawi Publishing Corporation Case Reports in Gastrointestinal Medicine Volume 2014, Article ID 319162, 3 pages http://dx.doi.org/10.1155/2014/319162 Case Report Severe Recurrent Pancreatitis in a Child with ADHD after Starting Treatment with Methylphenidate (Ritalin) Suheil Artul,1,2 Faozi Artoul,3 George Habib,4 William Nseir,2,4 Bishara Bisharat,2,4 and Yousif Nijim5 1 Department of Radiology, Nazareth Hospital, EMMS, Faculty of Medicine, Bar-Ilan University, Israel 2 Faculty of Medicine in the Galilee, Bar-Ilan University, Safed, Israel 3 Department of Nuclear Medicine, Meir Hospital, 44410 Betah Tekva, Israel 4 Department of Internal Medicine, EMMS Hospital, 16100 Nazareth, Israel 5 Pediatric Department, Nazareth Hospital, Israel Correspondence should be addressed to Suheil Artul; [email protected] Received 9 November 2013; Accepted 5 January 2014; Published 11 February 2014 Academic Editors: H. Kawaratani, J. Vecht, and O.¨ Yonem¨ Copyright © 2014 Suheil Artul et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. We present a case of a 10-year-old boy, who had severe relapsing pancreatitis, three times in two months within 3 weeks after starting treatment with methylphenidate (Ritalin) due to attention deficit hyperactivity disorder (ADHD). Pancreatitis due to the use of (methylphenidate) Ritalin was never published before. Attention must be made by the physicians regarding this possible complication, and this complication should be taken into consideration in every patient with abdominal pain who was newly treated with Ritalin. 1.
[Show full text]